Rezolute, Inc. — Form 8-K
Filed November 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Rezolute announced that its Phase 3 upLIFT study of ersodetug achieved its primary efficacy endpoint on November 5, 2026. Of 16 enrolled participants, 13 met the responder criterion (≥50% reduction in glucose infusion rate from baseline), exceeding the statistical threshold of 9 responders (56%) required for significance; 12 of these also achieved complete IV glucose discontinuation. Topline results with full statistical analysis are expected by mid-December 2026, with FDA pre-BLA meetings planned for Q1 2027 for both tumor HI and congenital HI indications.
Why this rating
Late-stage biotech with single asset; positive Phase 3 endpoint directly de-risks regulatory path and near-term value inflection. Significant relative to ~$259M market cap.
Tradability signal
NO TRADE
No trade: positive news with only -0.6% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.09% over 4 hrs, n=474). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $4.27 ▼ 5.11% | at our read · unknown $4.50 | +10 min · unknown $4.22 ▼ 6.11% | +30 min · unknown $3.83 ▼ 14.89% | +1 hr · unknown $3.73 ▼ 17.22% | +4 hrs · unknown $3.79 ▼ 15.67% |
The stock had already moved +5.39% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.